Comprehensive characterization of Etanercept using the ZenoTOF 7600 system

Comprehensive_characte_rization
Etanercept is a recombinant Fc fusion protein therapeutic that has a complex distribution of post-translation modifications (PTM), such as N and O-linked glycans. Current CID-based MS/MS can struggle to characterize such PTMs, since side-chain species are typically fragmented via a mechanism that does not produce diagnostic ions related to the PTM localization. Other forms of fragmentation, such as ETD, can maintain side chain information but suffer from low sensitivity and scan rate, as well as inadequate coverage of low charge state peptides. In this study, a new form of fragmentation (electron activated dissociation, or EAD) was employed to comprehensively characterize the glycosylation of etanercept at the peptide level. A comparative analysis between intact/subunit and peptide mapping results was performed as a validation step for the novel EAD workflow. Three N linked glycosylations were detected, as well as nine sites of O-linked glycosylation, with high confidences, via a single, generic, data-dependent LC-MS/MS analysis. Even in challenging cases, exact positioning information of the glycosylation on the peptide could be obtained. EAD also allows for confirmation of amino acid isomers (Leu/IsoLeu and Asp/IsoAsp) via MS/MS analysis, in the same experiment.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Decoding Antibody Discovery—The Future of Next-Gen Biologics

Antibodies have established themselves as one of the most important classes within the biologics space, and developing these therapeutics requires a series of successful decisions throughout the early-discovery process.
Watch Now

DNA Sequencing For Cancer Research

GE Healthcare Life Sciences

Through genomic sequencing and analysis, clinicians can identify specific mutations present in a patient’s cancer cells and deliver personalized treatment based on the genetic information. Increased availability and lower costs of next-generation sequencing (NGS) and analysis, along with the on-going identification of an expanding array of cancer-related genetic mutations and biomarkers, are enabling exponential growth in the use of this diagnostic and therapy-targeting tool.
Watch Now

2019 Joint Commission National Patient Safety Goals: Update and Practical Advice

Lorman Education Services

Understand the update of the National Patient Safety Goals to be sure your organization is in compliance with the requirements. Each year healthcare providers must meet the requirements of the Joint Commission's National Patient Safety Goals as part of the accreditation process. Receive an overview and update of the 2019 National Patient Safety Goals. Receive practical advice to implement the goals. Failing to meet a requirement will result in a requirement for improvement. This information is critical to ensure you are aware of the requirements.
Watch Now

Why a CT scan and not an MRI? Do I need another cardiac echo? Diagnostic tests for cardiovascular patients

esc365

After watching the webinar, participants will understand: which diagnostic tests are recommended for chronic vs. acute CV patients; and the diagnostic capabilities of noninvasive tests.
Watch Now

Spotlight

resources